Cytomx Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytomx Therapeutics, Inc. on October 4, 2021, reporting events that occurred on September 29, 2021. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial performance data.
Material Changes
On September 29, 2021, Alan Ashworth, Ph.D., FRS, was appointed to the Board of Directors as a Class III director. His initial term expires at the 2024 annual meeting of stockholders, filling a vacancy.
Compensation and Arrangements
- Equity Grant: Dr. Ashworth received an option to purchase 40,000 shares of common stock under the 2015 Equity Incentive Plan.
- Exercise Price: Set at the closing price of the Company's common stock on September 29, 2021.
- Vesting Schedule: The option vests monthly, with 1/36th of the shares becoming exercisable on each monthly anniversary of the appointment, contingent on continued service.
- Other Compensation: Dr. Ashworth will receive standard non-employee director compensation as outlined in the preliminary proxy statement filed on April 28, 2021.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Ashworth.
The Company confirmed there are no transactions exceeding $120,000 involving Dr. Ashworth since the beginning of the last fiscal year, nor any arrangements regarding his appointment other than those disclosed.
Investor Verification Checklist
- Verify the closing stock price on September 29, 2021, to determine the exercise price of the 40,000 share option.
- Review the preliminary proxy statement filed on April 28, 2021, for details on standard non-employee director cash compensation.
- Confirm the total number of shares authorized under the 2015 Equity Incentive Plan to assess the impact of this grant.
- Check subsequent filings for any updates to the Board composition or Dr. Ashworth's service status.